Eugit Therapeutics

Abalone Bio is tackling challenging undrugged targets underlying diseases affecting millions, focusing first cell-specific antibody drugs to treat obesity and metabolic disease without the GI side effects that cause 25% of GLP-1 drug patients to quit after 1 year. + High throughput experimental measurement uniquely leverages AI/ML: We’ve engineered cells to measure antibodies for pharmacological activity, not just structure or binding like others, 100 million at a time, 100X+ the throughput of o

shared product terms: target, disease, affect, million; shared product theme: health and clinical care; same category: AI infrastructure; shared affiliation: Y Combinator

SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis

shared product terms: therapeutic, drug, cause, clinical; shared product theme: health and clinical care; shared affiliation: Y Combinator

Nanograb is a computational drug discovery company that uses AI to create novel targeted non-viral gene therapy vectors. Our platform designs unique combinations of small peptide binders attached to nanoparticles to safely deliver genetic medicines to specific cells and tissues in the body at scale.

shared product terms: target, non, specific, drug; same category: AI infrastructure; shared affiliation: Y Combinator

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response

shared product terms: specific, drug, clinical, tissue; shared product theme: health and clinical care; same category: AI infrastructure; shared affiliation: Y Combinator

Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving the hidden root cause of most drug failures. Founded by Arvid (Broad Institute of MIT and Harvard; Nature-published researcher who pioneered quality-aware, goal-directed sparsification) and David (Harvard Medical School Gastroenterology, J&J), second-time founders

shared product terms: drug, toxicity, efficacy, cause; shared product theme: health and clinical care; same category: AI infrastructure; shared affiliation: Y Combinator

Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in

shared product terms: two, within, target, specific; shared product theme: health and clinical care; shared affiliation: Y Combinator